<DOC>
	<DOCNO>NCT00372476</DOCNO>
	<brief_summary>This study design investigate safety efficacy combination imatinib vinorelbine patient advance , anthracycline resistant breast cancer</brief_summary>
	<brief_title>Efficacy Safety Imatinib Vinorelbine Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : Histologically document diagnosis invasive breast cancer locally advance metastatic Previous anthracycline contain chemotherapy Presence certain protein cell surface ( ckit ( CD117 ) /or PDGFreceptor ) Preferably tumor sample take within 6 week study entry . Most recent primary tumor tissue available analysis Acceptable health status ( Eastern Cooperative Oncology Group [ ECOG ] performance status 0,1 , 2 3 ) Exclusion criterion : ( secondline therapy ) Patient Grade III/IV cardiac problem ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . Patient known brain metastasis , chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) diagnosis ( HIV ) infection . Patient receive chemotherapy within 4 week prior study entry , unless disease rapidly progress . Patient previously receive radiotherapy â‰¥ 25 % bone marrow major surgery within 2 week prior study entry . Patient receive either Vinorelbine Imatinib previous treatment regimens Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Tyrosine inhibitor</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Imatinib</keyword>
</DOC>